Sinthesis of new molecules and study in cellular senescense phenotyopes for the treatment of age-related diseases
In recent decades, life expectancy worldwide has increased considerably, but with it has come an increase in the prevalence of chronic diseases associated with aging, which are responsible for the majority of disabilities and deaths in the elderly population. This is largely due to cellular senescen...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/88897 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/88897 |
| Access Level: | acceso abierto |
| Palabra clave: | 576.385(043.2) Celúlas Cells Envejecimiento Aging Biología celular (Biología) 2407 Biología Celular |
| Sumario: | In recent decades, life expectancy worldwide has increased considerably, but with it has come an increase in the prevalence of chronic diseases associated with aging, which are responsible for the majority of disabilities and deaths in the elderly population. This is largely due to cellular senescence, a process in which cells acquire an irreversible cell-cycle arrest and become senescent, ceasing to repairtissues and secreting a series of substances that generate inflammation in adjacent tissues. In recent years, new drugs targeting cellular senescence have been identified and are in preclinical/clinical studies for the treatment of different age-related diseases such as cancer, idiopathic pulmonary fibrosis, chronic kidney disease, hepatic steatosis, neurological disorders, type 1 and 2 diabetes mellitus, osteoporosis, osteoarthritis, atherosclerosis, and other cardiovascular pathologies. They are known as senotherapeutic agents and, according to their mode of action, are classified as senolytics (eliminating senescent cells) or senomorphics (suppressing the senescence phenotype and slowing down its harmful effects). However, clinical trials are progressing slowly and to date, no senotherapeutic drug has been approved... |
|---|